People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Grail, Inc. | — | Biotechnology | Growth/Late | $2.2B | $2.9B | 2019 |
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2013 |
| Iambic Therapeutics, Inc. | — | Biotechnology | Series D+ | $240.9M | $697.8M | 2023 |
| Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) | — | Pharmaceuticals | Series A | $30.5M | $334.7M | 2009 |
William Rastetter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Rastetter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 3 | 22 |
| Amir Nashat | 2 | 14 |
| PAUL Grayson | 2 | 5 |
| Robert T. Nelsen | 2 | 5 |
| William T. Rastetter | 2 | 2 |
| Bryan Roberts | 1 | 18 |
| Kristina Burow | 1 | 16 |
| Michael Lee | 1 | 15 |
| Jishnu Bhattacharjee | 1 | 9 |
| Robert Epstein | 1 | 8 |
| Carl Weissman | 1 | 8 |
| Robert Nelson | 1 | 7 |
| Richard Klausner | 1 | 7 |
| Doug Cole | 1 | 6 |
| Bryan E. Roberts | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| R. Jacob Vogelstein | 1 | 6 |
| Thomas Miller | 1 | 5 |
| Faheem Hasnain | 1 | 5 |
| MIN CUI | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.